Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
01:37pm, Friday, 24'th Oct 2025
Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixen
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
01:37pm, Friday, 24'th Oct 2025
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
11:06am, Friday, 24'th Oct 2025
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
10:47am, Friday, 24'th Oct 2025
Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
02:55am, Friday, 24'th Oct 2025
Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged
01:35am, Friday, 24'th Oct 2025
France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines.
Press release: Q3: continued sales and earnings progress
01:30am, Friday, 24'th Oct 2025
Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching �
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
01:00am, Thursday, 23'rd Oct 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care Expanded 10-plus-year collaboration will
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
11:20am, Wednesday, 22'nd Oct 2025
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically mean
Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
07:05am, Friday, 17'th Oct 2025
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant
